• David Abejón, Tim Vancamp, and Eva M Monzón.
• Pain Unit, Hospital Universitario Quiron Salud, Madrid, Spain.
• Anesth Pain Med. 2020 Feb 1; 10 (1): e100308.

BackgroundSpinal cord stimulation (SCS) is an effective treatment option to relieve chronic intractable pain, and failed back surgery syndrome (FBSS) is a key indication.ObjectivesThe objective of the current study was to analyze the cost consequences of using non-rechargeable (NR)-SCS and rechargeable (R)-SCS.MethodsReal data taken from a review of 86 patients were used to simulate costs and review which patients might have benefitted more from R-SCS. Calculations were made to see what is the impact from a monetary point of view.ResultsOn average, NR-SCS devices lasted for 58 months (M). Only 14 patients were not eligible to receive an R-SCS implant. We found that using R-SCS batteries would save up to €56.322 on average over a patient's life expectancy, which means a saving of 43% compared to using NR-SCS systems. In our analysis, we found that if R-SCS implants were used instead of NR-SCS batteries, a saving of €5,735,334.23 over patients' life expectancy would be made, which represented a 63% saving to the public health system. We found that R-SCS was cost-beneficial from second year compared to NR-SCS, saving up to 70% when patients are implanted for 9 years.ConclusionsThis cost-consequences analysis suggests that R-SCS implants are more cost-beneficial than NR-SCS systems in well-selected patient candidates for this type of treatment.Copyright © 2020, Anesthesiology and Pain Medicine.

5 keywords...

hide…